Hepatitis C virus (HCV) infection is the most prevalent chronic blood-borne infection in the United States [1] . Nationally, it is estimated that <10% of HCV-infected persons have received treatment and achieved sustained virologic response (SVR) or cure [2] . In New York City (NYC), where an estimated 146 500 persons (2.4% of the population aged ≥20 years) are infected with HCV, the proportion cured (12%-15%) is similar to that seen in national data [3] .
Chronic HCV infection is commonly associated with persons who are marginalized in the healthcare system, with injection drug use (IDU) the primary risk factor in the United States [4] . Patients with sociobehavioral and comorbid conditions such as homelessness, psychiatric illness, and human immunodeficiency virus (HIV) coinfection have historically been classified as difficult to treat and have required increased support to access HCV care [5, 6] . Since highly effective, well-tolerated HCV medications became available in late 2013 [7, 8] , the impetus for public health efforts to support HCV-infected persons from diagnosis to cure has increased. Despite few clinical contraindications to use of interferon-free, direct-acting antiviral medications, some medical providers remain reluctant to initiate treatment for difficult-to-treat patients, and insurance providers restrict use due to medication cost [9] [10] [11] .
Gaps in the HCV care continuum following diagnosis include engagement in medical care, treatment initiation, and achieving SVR [12] . Patient navigation (PN) is an intervention used in chronic and infectious disease management to improve health outcomes by addressing patient-and systems-level barriers to care and treatment. Patient navigation services have been particularly effective in improving health outcomes in low-income and minority populations, who often experience the greatest health disparities. Evidence shows the effectiveness of patient navigation programs in improving health outcomes, including in diseases such as HIV and cancer [13] [14] [15] [16] [17] ; however, to date, there is no ongoing national or state funding for HCV patient navigation programs, and comparatively limited data on the efficacy of such programs have been reported [18, 19] .
In 2012, the NYC Department of Health and Mental Hygiene (DOHMH) developed and implemented a demonstration year of a patient navigation program, "Check Hep C, " with private industry funding. Check Hep C screened 4751 persons for HCV and linked 85% of those HCV infected (most of whom were at high risk for poor outcomes) to medical care and treatment. While a high proportion of HCV-infected participants had a first medical visit (85%, n = 435), only 6 were known to have successfully completed treatment in the program's demonstration year [19] . A second year of the program was made possible through additional private industry funding, and the program's scope was refined according to lessons learned in a demonstration year, shifting the focus from HCV screening and linkage to care to providing clinical patient navigation services to persons diagnosed with chronic HCV. The primary programmatic goals for year 2 were to support persons diagnosed with chronic HCV infection to complete a medical evaluation, access and initiate treatment, and achieve SVR.
We evaluated the Check Hep C patient navigation program by calculating rates of HCV medical evaluation, treatment initiation, completion, and SVR among participants and compared these rates between participants who received on-site clinical care to those receiving off-site care. We also identified patient demographics and other characteristics associated with treatment initiation and SVR.
METHODS

Site Selection and Description
Check Hep C year 2 was implemented at 4 community-based organizations in NYC. These sites had participated in the program's demonstration year and were selected for continuation based on their superior performance linking HCV-infected persons to medical care. Two sites were Federally Qualified Health Centers (FQHCs) with on-site clinical care, harm reduction, and social services. The other 2 sites were harm reduction and syringe exchange programs that linked participants to external medical care. These sites primarily provided support for linkage to care, maintenance in care, and return to care throughout the course of medical evaluation and treatment. The sites were located in neighborhoods with high HCV prevalence, and all programs served predominantly low-income and minority populations.
Patient Navigator and Multidisciplinary Team Characteristics
Four patient navigators (PNs) were employed under the Check Hep C program in year 2, one at each site. All PNs had a bachelor's degree, one was in nursing school, and one was in social work school. Only one PN had previous experience working with HCV-infected patients. Two PNs were bilingual in English and Spanish. A PN supervisor was designated at each site to oversee the program and participate directly in program management, communication, meetings, and site visits. The PN was responsible for facilitating the formation of and working closely with a multidisciplinary care team of clinical and supportive staff.
Program Implementation
The DOHMH developed a standardized patient navigation protocol, adapted from the DOHMH HIV Care Coordination protocol detailing program services (Appendix A). The 4 sites aimed to enroll 400 HCV-infected persons in the second year, recruited internally from the on-site organizations and through external outreach. The PNs evaluated patient needs through a comprehensive assessment, consisting of questions on physical and mental health, substance use, and social support. A care plan was then developed for each participant, individualized for participant and site characteristics (included in Appendix B).
Participants received clinical care either on-site at FQHCs ("on-site") or with external clinical providers for those enrolled at harm reduction sites ("off-site"). On-site care participants received clinic-based navigation, where the PN worked in the same clinic as the HCV provider and had direct access to electronic health records. Off-site care participants were linked to an external clinical provider for HCV care. All participants received appointment accompaniment (if needed), alcohol counseling, health education and motivational interviewing, and treatment readiness counseling (Appendix B). Regardless of location of the clinical provider, PNs supported participants through medical evaluation, preparation for antiviral treatment, and treatment adherence. Clinical providers determined treatment eligibility based on clinical and psychosocial factors. Treatment-eligible patients received health promotion, treatment readiness counseling, and medication adherence counseling and support. PNs additionally provided insurance and medication prior authorization support to the HCV medical providers, followed, where needed, by appeal and fair hearing applications to patient appeal boards.
Data Collection and Measures
PNs sent data electronically to DOHMH every month, including information on participant demographics, sociobehavioral conditions (homeless, IDU, current alcohol use, chemical dependence, and history of previous treatment), comorbidities (HIV coinfection, mental health conditions, diabetes, obesity, and heart disease) and program services delivered. Data were used to monitor program progress, identify areas for quality improvement, and evaluate participant outcomes. Measures to evaluate clinical program outcomes were HCV treatment initiation and undetectable HCV viral load for ≥12 weeks after end of treatment (SVR). Final data on SVR were collected through DOHMH surveillance as of 1 March 2016. The evaluation included only participants enrolled between April 2014 and January 2015 to allow enough time for patients to proceed through the HCV care cascade.
Univariate analysis was used to describe participant characteristics, including demographics, sociobehavioral conditions, and comorbidities at the time of assessment. For the evaluation, we characterized patients as high or low need based on the results of the assessment, designating patients with one or no sociobehavioral or mental health conditions as low need and those with ≥2 sociobehavioral or mental health conditions as high need. The associations between participant characteristics, clinical care type, and the primary outcomes were tested with bivariate χ 2 tests or Fisher exact tests. Multivariable logistic regression was employed to examine associations between the outcome measures and participant characteristics that were significant in the bivariate analysis. Mean SVR rates among participants who initiated treatment and exact confidence limits were calculated, stratified by participant characteristics. Statistical significance was defined as α = .05, with marginal significance in adjusted models reported at α = .10. Analyses were performed in SAS (version 9.2, Cary, North Carolina) [20] .
RESULTS
Between April 2014 and January 2015, Check Hep C enrolled 388 participants (Table 1 ). Most were Hispanic or black non-Hispanic. The median age of participants was 52 years, and 61% of participants were born between 1945 and 1965. Data showed that 29% reported IDU in the last year, 25% were homeless at time of enrollment, 28% reported a mental health condition, and 49% reported noninjection current chemical dependence in past year (including opioid agonist therapy). Fifty-one percent of participants received off-site clinical care and 44% received on-site clinical care. Five percent of participants were lost to follow-up before completing the patient navigation assessment, and were therefore not assigned a clinical care site type and removed from analysis. Participant characteristics varied by onand off-site care; however, participants designated as high and low need were equally distributed by clinical care type ( Table 2 ). The HCV care cascade for the Check Hep C program is presented in Figure 1 . Of the 388 enrolled participants, 299 (77%) completed an HCV medical evaluation. Of those medically evaluated, 79% of participants were determined treatment eligible, or 61% of all program participants. The primary reasons reported for treatment ineligibility were active drug use (n = 22), comorbid conditions (n = 13), or current alcohol use (n = 11). More than half (55%) of treatment-eligible candidates initiated treatment during the program period (33% of all program participants), and of those, 93% completed treatment and 91% achieved SVR. The HCV care cascade was stratified by clinical care setting and is presented in Figure 2 . Of those medically evaluated, 86% of on-site participants were determined to be treatment eligible compared with 73% of "off-site" participants, giving on-site participants twice the odds of a treatment-eligible determination (odds ratio [OR], 2.27; 95% confidence interval [CI], 1.22-4.35). On-site participants had a >2 times greater odds of initiating treatment (46% vs 25% for off-site participants) (Table 4) . Among those who initiated treatment, 94% of on-site participants achieved SVR compared with 86% of off-site care participants, with no statistical differences in SVR rates between the 2 care settings. However, among all Check Hep C participants, those who received on-site care had more than twice the odds of SVR (43%) compared with those who received off-site care (22%; OR, 2.74; 95% CI, 1.74-4.31).
In bivariate analyses examining factors associated with HCV treatment initiation (Table 3) , male participants had lower odds of initiating treatment while participants born between 1945-1965 had almost twice the odds of initiating treatment vs all other age groups. Other sociobehavioral factors associated with lower odds of initiating treatment included homelessness, IDU, alcohol use, and chemical dependence. Persons with a high fibrosis score (F3 or F4) had more than twice the odds of initiating treatment, in addition to those receiving on-site clinical care. Patient navigators anecdotally reported that the most common reasons for delayed treatment initiation were competing comorbid conditions, IDU, alcohol use, and psychiatric conditions. No differences in odds of initiating treatment were seen by race or comorbidity.
Adjusting for all significant variables found in bivariate analyses, a multivariable model showed that absence of alcohol use and high fibrosis score remained significantly associated with HCV treatment initiation (Table 4) . On-site clinical care was weakly associated with increased odds of treatment initiation, and IDU was weakly associated with decreased odds of treatment initiation (P = .09 for each).
For participants who initiated treatment, there were no demographic, sociobehavioral, or comorbid characteristics associated with treatment completion or SVR rates (Figure 3) . One hundred twenty-nine participants completed treatment, of whom 117 were known to have achieved SVR as of 1 March 2016.
DISCUSSION
The results of this study demonstrate the utility of patient navigation services in supporting chronically infected HCV patients in achieving care outcomes, particularly HCV care and cure. Year 2 of Check Hep C shifted the program focus from screening and linkage to care to patient navigation to supporting previously diagnosed patients to engage in medical care, successfully complete treatment, and attain SVR. The revised scope of services yielded a notably higher number and percentage of participants initiating treatment compared with year 1 of the project (129 [33%] vs 14 [3%], respectively) [19] . Overall, the SVR rate for Check Hep C enrollees was 30%, a 2-to 3-fold increase over the estimated 10%-15% SVR rates in the United States and NYC-wide [2] .
On-site, clinic-based patient navigation services may be more successful than off-site care services in initiating participants on HCV treatment. The findings suggest that a greater proportion of on-site patients than off-site participants were determined to be treatment eligible following the medical evaluation. This factor may be influenced by providers' increased willingness to treat high-need persons who are supported through treatment by a PN who is co-located at the clinical site. Of all enrollees, almost twice as many on-site care patients were known to have initiated treatment as part of the program. Adjusting for differences in participant characteristics, the results suggest that on-site clients may be more likely to initiate treatment, a finding consistent with studies that support single-site, integrated care models to improve clinical outcomes [21, 22] . This type of patient navigation may be recommended for clinically complex patients or participants with risk factors that would benefit from being co-managed by the PN and provider.
All participants who initiated treatment, regardless of clinical care site type, experienced high rates of treatment completion and SVR; 86% (43) of off-site patients and 94% (74) of on-site patients who initiated treatment achieved SVR. The off-site SVR rates are comparable to those achieved in other real-life studies, and the on-site rates are comparable to those observed in clinical trials [23, 24] . No differences in treatment completion or SVR rates were observed by demographics, sociobehavioral characteristics, or comorbid conditions, suggesting that for both on-site and offsite care, patient navigation services are successful at overcoming previously observed barriers to cure among HCV-infected individuals. Off-site participants may have been less likely to return for SVR laboratory testing following treatment completion, negatively impacting the observed rates of SVR. These SVR results demonstrate the real-world effectiveness of the new direct-acting antiviral medications and support their use in treating all patients, regardless of sociobehavioral or HCV risk history.
Clinical care improvements are needed to eliminate disparities in treatment initiation for historically difficult-to-treat populations. Treatment ineligibility caused by current alcohol use and active or recent IDU remains a barrier to HCV treatment initiation. These sociobehavioral conditions, coupled with comorbid conditions, were reported by PNs as the most common reasons that clinical providers did not treat otherwise eligible patients. PNs may require further training on how to support medical care for patients with active illicit drug or alcohol use and common comorbidities such as diabetes, renal disease, and mental health conditions. Additionally, education and training for clinical providers on updated HCV treatment guidelines and on managing complex cases may increase treatment eligibility determinations. Two additional factors associated with treatment initiation, high liver fibrosis score and absence of IDU, were likely driven by insurance restrictions for antiviral medications. In 2014, health insurers introduced strict guidance on prescribing the first of the newer highly effective drugs for HCV infection, which has prevented many patients from gaining treatment access (eg, limiting access to patients in the late stages of liver disease). Managed care companies often apply additional restrictions that can exclude active injection drug users and those with an uncontrolled HIV RNA load, likely because they are perceived as unable to adhere to HCV treatment regimens. Since the prescriber guidelines were issued, a substantial number of rejections on prior authorization for the new drugs have been reported [25] , thereby denying a cure to many patients who will face continued progression of liver disease. The latest American Association for the Study of Liver Diseases treatment guidelines support treatment for all HCV-infected persons, and further contend that the most immediate benefits of treatment will be realized by populations at highest risk for liver-related complications, including injection drug users [26] .
Patient navigation, as delivered in the Check Hep C program, successfully supported high-need patients through HCV care and treatment in both clinical and community-based healthcare settings. Increasing the availability of patient navigation services at organizations serving people at risk for or living with HCV in NYC would increase the number of people who successfully complete HCV medical treatment and cure. The patient navigation-focused intervention costs approximately $978 per patient enrolled. The cost per patient is low compared with that of treating complications of HCV infection [27, 28] . We recommend support of patient navigation services in more clinical settings to improve health outcomes of people with HCV, reduce costs to the healthcare system associated with long-term consequences of HCV infection, and increase HCV clinical care capacity.
The Check Hep C evaluation was subject to several limitations. Patient navigators were responsible for data entry, which may have led to data errors because this task competed with providing patient support and was viewed as less important by the PNs. Data entry and reporting quality were monitored closely by DOHMH staff; monthly data quality feedback was provided to PNs at in-person program management meetings and by email, and a minimum of 2 quality assurance site visits were conducted at each site during the program. An extension made possible through NYC Council support of the program through July 2015 allowed DOHMH to receive longer-term data from the sites and conduct more in-depth quality control on the data. Because the program was implemented at only 4 community-based centers, a relatively small number of patients was served. As there was no control group, comparative improvements in the HCV care cascade could not be estimated. The barriers to care examined in this study represent the factors associated with a unique, densely urban population, potentially making the findings less generalizable to other US locations but replicable in other urban areas.
CONCLUSIONS
Patient navigation services delivered through Check Hep C successfully engaged patients in HCV medical care and supported patients who initiated HCV treatment through to cure. The patient navigation strategies can be used in clinic-and community-based healthcare organizations serving high-need populations to support HCV treatment and cure. Clinic-based patient navigation services in particular can improve the HCV care continuum. The success of programs such as Check Hep C can be used to support policy changes that ensure the availability of funding or insurance reimbursement for HCV-specific patient navigation and care coordination services. Sustainable patient navigation services for HCV infection are essential to improve clinical outcomes in high-need persons and to end the HCV epidemic.
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